I
ImmuneID
Biotech & Life Sciences · Waltham, United States · Founded 2020
Enabling precision immunology MoreLess
ImmuneID is a cutting-edge precision immunology company that aims to revolutionize the understanding and treatment of immune diseases. The company leverages its proprietary, genome-wide, high-throughput platform to identify and target millions of antibody interactions. This advanced technology allows ImmuneID to gain a comprehensive understanding of individual immune responses, which is crucial for developing precise and effective therapies.
The primary clients of ImmuneID include pharmaceutical companies, biotechnology firms, and research institutions that are focused on immunology and related fields. These clients benefit from ImmuneID's ability to provide detailed insights into immune responses, which can significantly enhance the development of new drugs and therapies.
ImmuneID operates in the biotechnology and healthcare markets, specifically within the niche of precision medicine and immunology. The company's business model is based on offering its proprietary platform as a service to its clients. This involves conducting detailed analyses of immune responses and providing actionable data that can be used to develop targeted therapies. Additionally, ImmuneID may engage in partnerships and collaborations with other companies to co-develop new treatments.
Revenue generation for ImmuneID primarily comes from service fees charged to clients for using its platform. The company may also earn income through collaborative agreements, licensing deals, and potentially from the commercialization of co-developed therapies.
In summary, ImmuneID is a precision immunology company that uses advanced technology to unlock the complexities of human immune responses, serving pharmaceutical and biotech clients in the healthcare market. The company makes money by providing detailed immune response analyses and through partnerships and licensing agreements.
Keywords: precision immunology, antibody interactions, immune diseases, biotechnology, healthcare, genome-wide platform, pharmaceutical clients, biotech firms, targeted therapies, immune response analysis.
Valuation & funding
ImmuneID funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2021 | $50M | $200M | Xfund · Longwood Fund · Tekla Capital Management · In-Q-Tel | — |
| EARLY VCOther financing | Feb 2021 | $17M | $68M | Pitango Venture Capital · Longwood Fund · ARCH Venture Partners · In-Q-Tel | — |
| SPINOUTOther financing | Jan 2020 | $0 | — | Harvard University · Johns Hopkins University | — |
Growth signals
ImmuneID website traffic
Latest recorded traffic for ImmuneID is 150 monthly website visits, down 60.5% over the last three months. ImmuneID's team grew 0% over the past year.
Comparisons
ImmuneID compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ImmuneID's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where ImmuneID has talent and traffic
In the news
Latest news about ImmuneID
Recent press, funding announcements, and product moves mentioning ImmuneID — open to read from the original sources.
Market sentiment
What the market is saying about ImmuneID
An AI-synthesized read of the highest-engagement posts about ImmuneID on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImmuneID’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.